IBIO INC (IBIO)
US4510336096 - Common Stock
0.752 -0.04 (-4.81%)
After market: 0.76 +0.01 (+1.06%)
iBio to Participate in the JMP Securities Life Sciences Conference
BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision...
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody...
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas,...
7 Stocks to Sell as Banks Melt Down
Although the internet encourages you to buy the red ink, sometimes you should consider stocks to sell as just that.
Why Is Ambrx Biopharma (AMAM) Stock Down 15% Today?
Ambrx Biopharma (AMAM) stock is falling on Friday but it's not due to any negative news released by the medical company today.
Why Is VolitionRX (VNRX) Stock Down 17% Today?
VolitionRX (VNRX) stock is taking a beating on Friday after the company revealed a proposed public offering for its shares.
Why Is Nogin (NOGN) Stock Up 25% Today
Nogin (NOGN) stock is taking off on Friday with heavy trading volume after announcing an agreement with Seychelles Imports.
Why Is iBio (IBIO) Stock Up 124% Today?
Ibio (IBIO) stock is rocketing higher on Friday after the biopharmaceutical company announced a new immune-oncology program.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off the final trading day of the week with a look at the biggest pre-market stock movers worth watching on Friday!
iBio (NYSE:IBIO) announces new immuno-oncology target program
iBio (IBIO) on Thursday said it would target MUC16, a protein expressed in several types of cancers, for its latest immuno-oncology program. Read more here.
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
- Company has directed antibodies against a specific region of MUC16 - - Potentially offers a differentiated and effective tool in the fight against...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday!
iBio Announces Closing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody...
7 Penny Stocks to Sell Before They Plunge in 2023
These penny stocks to sell have been incredibly volatile this year and should be discarded from your portfolios heading into 2023.
25 Penny Stocks to Sell Before They Die
Wondering which small-cap companies you should offload before 2023? Here are the top picks for penny stocks to sell while you still can.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out the latest news traders need to know about on Wednesday!
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody...
iBio Announces Proposed Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody...
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody...
iBio's CEO, Thomas F. Isett departs (NYSE:IBIO)
iBio (IBIO) announced that the Board of Directors and Thomas F. Isett, company’s CEO, have agreed that Mr
iBio Announces CEO Departure
BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody...